Published May 21, 2022 | Version v1
Journal article Open

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study

Description

Table S1: Raw patient data used in this study. The following parameters are included: (1) Arbitrary patient number. (2) Gender; female (F) or male (M). (3) Age at DMF introduction (in of patients who received more than one courses of DMF, the age corresponds to the start of the first course). (4) “DM start”; date of DMF introduction. (5) “DM end”; date of DMF termination. The table also indicates if at least one TSH value was either in the reference range (normal, “n”) or below or above the reference range (abnormal, “ab”) before (6), during (7) or after (8) DMF treatment. In patients still receiving DMF treatment at the end of the present study, TSH value after DMF treatment is not applicable (“na”). (9) “dysthyroidism”; indicates the presence (“yes”) or absence (“no”) of thyroid gland disorders based on TSH values or the mention of thyroid gland disorders in the patients record. (10) “thyroid diagnosis” indicates specific thyroid gland disorders, whenever present. The following columns of Supplementary Table S1 describe the different multiple sclerosis-specific treatments that the patients received: treatment name (columns 11, 19, 27, 35, 43, 51, 59 and 67); treatment start date (columns 12, 20, 28, 36, 44, 52, 60 and 68); treatment end date (columns 13, 21, 29, 37, 45, 53, 61 and 69); dosage (columns 14, 22, 30, 38, 46, 54, 62 and 70); units (columns 15, 23, 31, 39, 47, 55, 63 and 71); frequency (columns 16, 24, 32, 40, 48, 56, 64 and 72); route of administration (columns 17, 25, 33, 41, 49, 57, 65 and 73); and, in case of discontinuation (columns 18, 26, 34, 42, 50, 58, 66 and 74), the specific reason, if known. Tables S2–S8 present the thyroid test results (TSH, total T3, free T3, total T4, free T4, anti-TPO, anti-Tg and anti-TSHR, whenever available) of the respective patients with abnormal thyroid test values. Table S2: Data of patient 9; Table S3: data of patient 15; Table S4: data of patient 62; Table S5: data of patient 97; Table S6: data of patient 103; Table S7: data of patient 121; Table S8: data of patient 153.

Files

Files (56.7 kB)

Name Size Download all
md5:13184d4e6db8fa11e75be62579f0d04f
56.7 kB Download

Additional details

Funding

Swiss National Science Foundation
Role of the Nrf2 response system in the pathogenesis of autoimmune thyroiditis 323530_199386
Swiss National Science Foundation
Impact of redox-active natural substances on thyroid pathophysiology. IZCOZ0_177070
Swiss National Science Foundation
Dissecting the cellular sources and immune functions of Oxysterols during Neuroinflammation 310030_192738
Swiss National Science Foundation
Roles of Keap1/Nrf2 signaling in thyroglobulin regulation: impact on goiter and thyroid carcinoma. 31003A_182105